Project Grant R01AA032953
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $2,072,751 under the Alcohol Research Programs (CFDA 93.273) on September 15, 2025. The recipient is conducting research into innate immune dysregulation in alcohol-associated liver disease, with focus on neutrophil heterogeneity and dysfunction in alcohol-associated hepatitis. The work characterizes transcriptomic profiles and functional roles of neutrophil populations—specifically...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of the Department of Health and Human Services National Institutes of Health, awarded Yale University $663,419 on August 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate liver sinusoidal endothelial cell (LSEC) inflammation in alcohol-associated liver disease. The research addresses mechanisms by which alcohol disrupts LSEC homeostasis through two converging pathways: IL6 trans-signaling mediated...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Health Science Center at San Antonio $664,792 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate post-transcriptional mechanisms and cellular senescence in age-related alcoholic liver disease. The research targets dysregulated nutrient sensing as a hallmark of aging that drives hepatic steatosis progression toward cirrhosis and hepatocellular carcinoma. The recipient will...
- The National Institute on Alcohol Abuse and Alcoholism awarded Cedars-Sinai Medical Center $1.235 million under the Alcohol Research Programs (CFDA 93.273) on September 10, 2025, to investigate the role of prohibitin 1 (PHB1) in ethanol's sensitizing effect on colorectal liver metastasis. Research will examine how excessive alcohol intake depletes hepatocyte nuclear and cytosolic PHB1, increasing matrix metalloproteinase-7 (MMP-7) expression and rendering the liver susceptible to colorectal...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $301,070 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate mechanisms that regulate hepatocyte fate during recovery from alcohol-associated hepatitis. The research addresses the pathogenesis of alcohol-associated liver disease, which progresses from simple steatosis to severe forms including alcoholic hepatitis, fibrosis,...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $596,476 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the role of acute phase response signaling in alcohol-associated liver disease resolution. The project, awarded as a Project Grant (R01AA032810), funds research examining how hepatocytes direct a resolution program following alcohol cessation, producing signals that alter liver...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $1.321 million on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate ITPR3 and aberrant mitochondrial calcium signaling in alcoholic hepatitis. The project examines how altered mitochondrial calcium signaling contributes to the development of alcohol-associated hepatitis (AAH), a severe complication of alcohol-associated liver disease with short-term mortality ranging from 20 to 50...
- The National Institute on Alcohol Abuse and Alcoholism awarded Trustees of Indiana University (Indiana University Indianapolis) $492,012 on September 12, 2025, as a Project Grant under the Alcohol Research Programs (CFDA 93.273) to investigate the mechanism of neutrophilic NCF1 in alcohol-associated liver disease pathogenesis. The research examines how neutrophils drive disease severity and mediate liver injury in alcohol-associated liver disease (ALD), with specific focus on the NCF1 gene's...